PDS Biotechnology (NASDAQ:PDSB) Receives Buy Rating from HC Wainwright

PDS Biotechnology (NASDAQ:PDSB - Get Free Report)'s stock had its "buy" rating reiterated by investment analysts at HC Wainwright in a report released on Wednesday,Benzinga reports. They currently have a $13.00 price objective on the stock.

Separately, Wall Street Zen upgraded shares of PDS Biotechnology from a "sell" rating to a "hold" rating in a report on Saturday, May 24th.

PDS Biotechnology Stock Up 3.4%

PDSB stock traded up $0.06 during midday trading on Wednesday, reaching $1.81. The company had a trading volume of 435,779 shares, compared to its average volume of 576,977. The company has a 50 day moving average of $1.31 and a two-hundred day moving average of $1.47. The company has a market capitalization of $82.74 million, a P/E ratio of -1.56 and a beta of 1.27. PDS Biotechnology has a 1 year low of $0.85 and a 1 year high of $4.42. The company has a current ratio of 2.84, a quick ratio of 2.84 and a debt-to-equity ratio of 0.55.

PDS Biotechnology (NASDAQ:PDSB - Get Free Report) last issued its earnings results on Wednesday, May 14th. The company reported ($0.21) earnings per share for the quarter, topping the consensus estimate of ($0.25) by $0.04. On average, equities research analysts expect that PDS Biotechnology will post -1.2 earnings per share for the current fiscal year.

Institutional Investors Weigh In On PDS Biotechnology

Hedge funds have recently bought and sold shares of the company. Iron Gate Global Advisors LLC acquired a new position in shares of PDS Biotechnology during the 1st quarter worth about $89,000. Armistice Capital LLC bought a new stake in shares of PDS Biotechnology in the first quarter valued at approximately $5,259,000. Blair William & Co. IL increased its position in PDS Biotechnology by 63.3% during the first quarter. Blair William & Co. IL now owns 257,200 shares of the company's stock worth $306,000 after acquiring an additional 99,700 shares during the period. Two Sigma Investments LP raised its stake in PDS Biotechnology by 273.5% during the 4th quarter. Two Sigma Investments LP now owns 65,732 shares of the company's stock valued at $107,000 after purchasing an additional 48,132 shares during the last quarter. Finally, Jane Street Group LLC bought a new stake in PDS Biotechnology in the 4th quarter valued at $58,000. 26.84% of the stock is currently owned by institutional investors.

PDS Biotechnology Company Profile

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies.